Merck & MRK
Merck & Company is a global pharmaceutical company that develops and commercializes innovative medicines (such as Keytruda) and vaccines, with a business model based on intensive R&D and sales through prescription and distribution channels. Merck shows exceptional momentum (93.24) and an attractive forward valuation (forward P/E 15.61), but its financial health is weighed down by a negative operating margin and an unsustainable payout, while dependence on Keytruda remains the main structural challenge.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Merck & Company is a global pharmaceutical company that develops and commercializes innovative medicines (such as Keytruda) and vaccines, with a business model based on intensive R&D and sales through prescription and distribution channels. Merck shows exceptional momentum (93.24) and an attractive forward valuation (forward P/E 15.61), but its financial health is weighed down by a negative operating margin and an unsustainable payout, while dependence on Keytruda remains the main structural challenge.
Score by category
| Category | Score |
|---|---|
| Financial health | 4.9 |
| Quality / Moat | 4.6 |
| Valuation | 4.5 |
| Growth | 5.7 |
| Dividend | 2.7 |
| Momentum | 9.8 |
| Risk & Context | 8.7 |
OVERALL SCORE: 5.6/10
Context and risks
Moderate regulatory risk in the US due to drug pricing pressure and patent litigation, especially the loss of Keytruda exclusivity later this decade. The new FDA approval partially mitigates this risk.
News considered in the analysis
- Merck Is Up 40% This Year, but Is the Keytruda Rebuild Already Priced In? — Cuestiona si el fuerte repunte de la acción ya descuenta el futuro post-patente de Keytruda, un riesgo conocido pero que el mercado sigue debatiendo.
- Merck (MRK) Stock May Be 37% Undervalued On Fresh FDA Approval — Una nueva aprobación de la FDA refuerza la cartera de productos y mitiga la dependencia de Keytruda, con impacto material en la valoración.
- MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Cancer Data — Noticia sobre Moderna, un competidor, sin impacto directo en los fundamentales de Merck.
- Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success And Middle East Expansion Talks — Noticia sobre Moderna, sin impacto directo en Merck.
- Is LLY Stock Cheaper Than It Looks? — Análisis sobre Eli Lilly, un competidor, sin información nueva sobre Merck.
Verdict: Hold; the new FDA approval and strong momentum are positive, but the high dependence on Keytruda and unsustainable payout warrant caution.
Main risk: The loss of exclusivity for Keytruda at the end of the decade, which represents a significant portion of revenue and profits, without a clear replacement in the pipeline.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →